Ascletis Pharma Inc. (HKEX: 1672), a China-based R&D driven biotech company, announced on Monday that it has received the Investigational New Drug (IND) application approval from United States Food and Drug Administration (FDA) and started global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for the functional cure of chronic hepatitis B.
The product has undergone the ASC22 Phase IIb study (ClinicalTrials.gov Identifier: NCT04465890), a randomised, single-blind, placebo-controlled, multi-centre clinical trial in China that assessed the efficiency and safety of 149 chronic hepatitis B patients for 24-week treatment of 1mg/kg or 2.5mg/kg ASC22 or matching placebo offered once every two weeks along with NAs.
Ascletis Pharma Inc has received a global and exclusive license effective 8 November 2021 from Suzhou Alphamab to develop and commercialise ASC22 for all viral diseases including Hepatitis B.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial